中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.018 seconds)

    싸이클로옥시게네이즈-2와 Ｐ５３의 상호작용 억제물질 스크리닝 방법
    2.
    发明公开
    싸이클로옥시게네이즈-2와 Ｐ５３의 상호작용 억제물질 스크리닝 방법 无效
    筛选抗癌药物抑制CYCLOOXYGENASE-2和P53相互作用的方法

    公开(公告)号：KR1020100023711A

    公开(公告)日：2010-03-04

    申请号：KR1020080105956

    申请日：2008-10-28

    Applicant: 강원대학교산학협력단

    Inventor： 한정아

    IPC: G01N33/574 ,  G01N33/561 ,  C12Q1/68

    CPC classification number: G01N33/15 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N27/26 ,  G01N33/53

    Abstract: PURPOSE: A method for screening an anti-cancer drug is provided to screen antagonism to tumorigenesis and metastasis based on the molecular mechanism of p53 suppression. CONSTITUTION: A method for screening an anticancer drug which suppresses the interaction of cyclooxygenase-2(COX-2) and p53 comprises: a step of contacting a COX-2 containing p53-binding domain(amino acid 1-126) or a fragment thereof with p53 having a DNA-binding domain under the presence of a test drug; and a step of determining the suppression of interaction between COX-2 and p53 by comparing with a control group in which a test drug is not contained. The interaction between the COX-2 and p53 occurs between the p53-binding domain of COX-2 and the DNA-binding domain of p53. The binding site of COX-2 and p53 is an amino acid of sequence number 2. The interaction of the COX-2 and p53 is measured through a GST pull down assay, immunoprecipitation assay, and EMSA(electrophoretic mobility shift assay).

    Abstract translation: 目的：基于p53抑制的分子机制，提供筛选抗癌药物的方法筛选肿瘤发生和转移的拮抗作用。 构成：用于筛选抑制环氧合酶-2（COX-2）和p53的相互作用的抗癌药物的方法包括：使含有COX-2的p53结合结构域（氨基酸1-126）或其片段 其中p53在测试药物存在下具有DNA结合结构域; 以及通过与不含有测试药物的对照组进行比较来确定COX-2和p53之间相互作用的抑制的步骤。 COX-2和p53之间的相互作用发生在COX-2的p53结合结构域和p53的DNA结合结构域之间。 COX-2和p53的结合位点是序列号2的氨基酸。通过GST下拉测定，免疫沉淀测定和EMSA（电泳迁移率变动测定）测量COX-2和p53的相互作用。

    싸이클로옥시게네이즈-2(ＣＯＸ－２)의 핵이동 억제물질 스크리닝 방법
    10.
    发明公开
    싸이클로옥시게네이즈-2(ＣＯＸ－２)의 핵이동 억제물질 스크리닝 방법 无效
    筛选防止COX-2进入核的抗癌剂的方法

    公开(公告)号：KR1020100023712A

    公开(公告)日：2010-03-04

    申请号：KR1020080105974

    申请日：2008-10-28

    Applicant: 강원대학교산학협력단

    Inventor： 한정아

    IPC: G01N33/574 ,  G01N33/533 ,  G01N33/68 ,  C12Q1/68

    CPC classification number: G01N33/15 ,  G01N21/64 ,  G01N2021/6406

    Abstract: PURPOSE: A method for screening an anticancer drug and an anticancer drug composition are provided to prevent and treat cancer. CONSTITUTION: A method for screening an anticancer drug which suppresses the nucleus movement of COX-2 comprises: a step of administering a test drug to a cell expressing a COX-2 containing epidermal growth factor(EGF)-like domain(amino acid 24-54) and a membrane-binding domain(MBD)(amino acid 59-111); and a step of determining the suppression of the nucleus movement of the COX-2 when DNA is damaged. COX-2 enters a nucleus and interacts with p53 when DNA is damaged. The EGF-like growth factor has an amino acid of sequence number 3. The DNA is damaged by doxorubicin, etoposide, or sctinomycin. The anticancer drug composition contains the screened drug as an active ingredient.

    Abstract translation: 目的：提供一种抗癌药物和抗癌药物组合物的筛选方法，以预防和治疗癌症。 构成：用于筛选抑制COX-2的细胞核运动的抗癌药物的方法包括：向表达含有COX-2的表皮生长因子（EGF）样结构域（氨基酸24-位）的细胞施用测试药物的步骤， 54）和膜结合结构域（MBD）（氨基酸59-111）; 以及当DNA损伤时确定COX-2的细胞核运动的抑制的步骤。 当DNA损伤时，COX-2进入细胞核并与p53相互作用。 EGF样生长因子具有序列号3的氨基酸.DNA被多柔比星，依托泊苷或正宗霉素损伤。 抗癌药物组合物含有筛选药物作为活性成分。

Patent Agency Ranking